Doximity, Inc.
NYSE:DOCSMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $5.47B
- Beta
- 1.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.06
Volume 2.27M
Average 3.89M
DOCS Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Doximity, Inc.NYSE: DOCS
Accounts Receivables · Q2 FY2027 · quarter ended Sep 2026
Accounts receivables dips below year-ago levels
Q2 FY2027 accounts receivables of $11.37M fell 8.3% year over year, behind the +703.4% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -13.7% a year.
Context
- Accounts receivables amounted to 2.6% of revenue in FY2026, down 2.2 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -8.3% toward the trailing-twelve-month pace of +703.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2026
- (16.88M) USD
- Year-over-year change
- +38.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | (16.88M) | +38.0% |
| FY2025 | 2025-03-31 | (27.21M) | -781.3% |
| FY2024 | 2024-03-31 | 3.99M | +115.2% |
| FY2023 | 2023-03-31 | (26.24M) | +15.4% |
| FY2022 | 2022-03-31 | (31.02M) | — |
Accounts Receivables vs competitors
How DOCS compares with its peers on the latest reported figures
- DOCS's LTM Sep 2026 accounts receivables of $37.86M is the 6th largest of the 10 companies compared; the peer median is $62.9M.
- Its year-over-year change of +703.4% is the highest of 9, against a peer median of -66.7%.
- Accounts receivables amounts to 5.7% of revenue for DOCS, versus a peer median of 1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $169M | -364.1% | — | 2.0% | |
| LTM Jun 2026 | $149.65M | -194.6% | -39.2% | 1.8% | |
| LTM Jun 2026 | $76.6M | -118.0% | — | 0.5% | |
| LTM Sep 2026 | $70.6M | +155.1% | — | 5.5% | |
| LTM Jun 2026 | $62.9M | +362.5% | -3.5% | 1.0% | |
| LTM Sep 2026 | $37.86M | +703.4% | -13.7% | 5.7% | |
| LTM Jul 2026 | $35.21M | -46.7% | — | 1.2% | |
| LTM Jul 2026 | $11.03M | +307.0% | -15.9% | 0.8% | |
| LTM Sep 2026 | $9.7M | -86.6% | +122.5% | 0.6% | |
| LTM Jul 2026 | $0 | — | +52.7% | 0.0% | |
| Peer median (excluding DOCS) | $62.9M | -66.7% | -3.5% | 1.0% | |
Competitors are the stored peer set for DOCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | 154.78M | 112.82M | 147.58M | 223.19M | 196.05M |
| Depreciation & Amortization | 5.04M | 10.28M | 10.27M | 10.66M | 14.38M |
| Deferred Income Tax | (41.25M) | 13.23M | (8.59M) | (11.59M) | 32.14M |
| Stock-Based Compensation | 31.44M | 47.83M | 51.08M | 72.39M | 121.63M |
| Change in Working Capital | (40.33M) | (21.03M) | (24.52M) | (24.1M) | (45.7M) |
| Accounts Receivables | (31.02M) | (26.24M) | 3.99M | (27.21M) | (16.88M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 8.66M | (195K) | 8.33M | (663K) | 4.27M |
| Other Working Capital | (17.98M) | 5.4M | (36.85M) | 3.77M | (33.09M) |
| Other Non-Cash Items | 16.89M | 16.47M | 8.29M | 2.72M | 7.96M |
| Operating Cash Flow | 126.58M | 179.6M | 184.1M | 273.27M | 326.46M |
| Capital Expenditures | (5.7M) | (6.18M) | (5.8M) | (6.53M) | (8.96M) |
| Acquisitions (Net) | 0 | (53.5M) | 0 | 0 | (26.53M) |
| Purchases of Investments | (1.32B) | (190.56M) | (472.87M) | (675.56M) | (389.16M) |
| Sales of Investments | 681.72M | 190.32M | 509.85M | 652.78M | 571.82M |
| Other Investing Activities | 595K | 0 | (5.65M) | 0 | 0 |
| Investing Cash Flow | (640.57M) | (59.92M) | 31.19M | (29.3M) | 147.17M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 553.91M | 0 | 0 | 23.3M | 13.68M |
| Common Stock Repurchased | (2.7M) | (85.32M) | (280.72M) | (120.29M) | (431.65M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.21M | 10.86M | 4.19M | (34.15M) | (46.09M) |
| Financing Cash Flow | 560.42M | (74.46M) | (276.52M) | (131.14M) | (464.06M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 46.42M | 45.22M | (61.24M) | 112.83M | 9.56M |
| Free Cash Flow | 120.88M | 173.42M | 178.3M | 266.74M | 317.5M |
Doximity, Inc.
NYSE:DOCS
Intrinsic Alpha fair value
Locked
Current Price
$30.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.